bluebird bio BLUE
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
bluebird bio (BLUE) Business Model and Operations Summary
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
Key Insights
bluebird bio (BLUE) Core Market Data and Business Metrics
Latest Closing Price
$5.25Market Cap
$51.46 MillionPrice-Earnings Ratio
-0.21Total Outstanding Shares
9.74 Million SharesTotal Employees
375Dividend
No dividendIPO Date
June 19, 2013SIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
455 Grand Union Boulevard, Somerville, MA, 02145
Historical Stock Splits
If you bought 20 shares of BLUE before December 13, 2024, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| December 13, 2024 | 1-for-20 (Reverse Split) |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities | $87.47 Million |
| Net Cash Flow From Financing Activities, Continuing | $87.47 Million |
| Net Cash Flow From Operating Activities, Continuing | $-260.02 Million |
| Net Cash Flow From Investing Activities, Continuing | $3.90 Million |
| Net Cash Flow From Investing Activities | $3.90 Million |
| Net Cash Flow | $-168.65 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Income/Loss From Continuing Operations After Tax | $-240.70 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $-240.72 Million |
| Cost Of Revenue | $89.38 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Basic Average Shares | $9.69 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss Attributable To Parent | $-337,000 |
| Comprehensive Income/Loss Attributable To Parent | $-241.05 Million |
| Comprehensive Income/Loss | $-241.05 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $-241.05 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Noncurrent Liabilities | $170.30 Million |
| Equity | $-31.53 Million |
| Intangible Assets | $9.55 Million |
| Equity Attributable To Parent | $-31.53 Million |
| Prepaid Expenses | $10.63 Million |
| Other Current Assets | $79.02 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||